Lupin Ends 2018 On High, Strikes Large MALT1 Deal With AbbVie

 
• By Anju Ghangurde

AbbVie has in-licensed Lupin’s MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor program for over $900m in potential milestone payments, bringing Christmas cheer for the Indian firm. The deal terms for the preclinical asset are rather striking.

Skydivers
LUPIN HAS LICENSED ITS EARLY STAGE ONCOLOGY ASSET TO ABBVIE

More from Business

More from Scrip